Showing results 13 to 18 of 18
< previous
Issue Date | Title | Author(s) |
7-Jun-2023 | MAT2A inhibition in AML unveils therapeutic potential of combining DNA demethylating agents with UPR targeting | Zeka, K; Taylor, AV; Samarista, R; Ragusa, D; Suen, C-W; Cyran, OC; Domingues, AF; Meduri, E; Huntly, BJP; Forte, D; Curti, A; Pina, C |
30-Jan-2023 | Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets | Ragusa, D; Dijkhuis, L; Pina, C; Tosi, S |
19-Dec-2023 | The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma | CicirĂ², Y; Ragusa, D; Nevado, PT; Lattanzio, R; Sala, G; Des Rochers, T; Millard, M; Andersson, M; Stenman, G; Sala, A |
29-Oct-2019 | MLL-rearranged acute leukemia with t(4;11)(q21;q23) - current treatment options. Is there a role for CAR-T cell therapy? | Britten, O; Ragusa, D; Tosi, S; Kamel, YM |
11-Nov-2022 | Pan-Cancer Analysis Identifies MNX1 and Associated Antisense Transcripts as Biomarkers for Cancer | Ragusa, D; Tosi, S; Sisu, C |
2019 | The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): revised characterisation of cytogenetic features | Ragusa, D; Makarov, E; Britten, O; Moralli, D; Green, C; Tosi, M |